1. Dear Drugs-Forum readers: We are a small non-profit that runs one of the most read drug information & addiction help websites in the world. We serve over 4 million readers per month, and have costs like all popular websites: servers, hosting, licenses and software. To protect our independence we do not run ads. We take no government funds. We run on donations which average $25. If everyone reading this would donate $5 then this fund raiser would be done in an hour. If Drugs-Forum is useful to you, take one minute to keep it online another year by donating whatever you can today. Donations are currently not sufficient to pay our bills and keep the site up. Your help is most welcome. Thank you.
    PLEASE HELP
  1. Alfa
    LONG TRIP FOR PSYCHEDELIC DRUGS

    Psychedelic drugs are inching their way slowly but surely toward
    prescription status in the United States, thanks to a group of persistent
    scientists who believe drugs like ecstasy and psilocybin can help people
    with terminal cancer, obsessive-compulsive disorder and post-traumatic
    stress disorder, to name just a few.

    The Heffter Research Institute, the Multidisciplinary Association for
    Psychedelic Studies and others have managed to persuade the Food and Drug
    Administration to approve a handful of clinical trials using psychedelics.
    The movement seems to be gaining ground in recent years. Since 2001, the
    FDA and the Drug Enforcement Administration have given the go-ahead to
    three clinical trials testing psychedelics on symptomatic patients, and
    several more are on deck.

    Doctors who saw their patients benefit from psychedelic drugs back when
    they were legal are dedicated to jumping through bureaucratic hoops and
    diminishing the drugs' party stigma to get psychedelics in patients' hands,
    and brains.

    "I'm interested in the treatment being available to people who need it, and
    doing it aboveboard and publishing good results," said George Greer,
    founder of the Heffter Research Institute, a scientific organization that
    organizes and funds trials involving psychedelics.

    At first blush, it seems like an uphill battle more challenging than the
    one medical-marijuana advocates have been facing. MDMA has been vilified by
    the National Institute on Drug Abuse and in news stories, making it seem
    unlikely that federal agencies will ever allow the legal use of psychedelics.

    But it might actually be easier to get psychedelics through the approval
    process than marijuana, according to Rick Doblin, founder and president of
    MAPS. The roadblock with marijuana has centered on supply. A
    government-controlled crop in Mississippi is the only marijuana the
    government will allow in clinical trials. But the supply of psychedelics is
    decentralized, and the researchers have control of much of it.

    Doblin's persistence and know-how -- he has a doctorate in public policy
    from Harvard's John F. Kennedy School of Government -- led to the launch of
    the first FDA-approved clinical trial testing MDMA as a therapy (in this
    case for post-traumatic stress disorder) since the drug became illegal.

    And now it looks like Doblin's alma mater may be close to launching the
    first psychedelic research that Harvard has allowed on its campus in almost
    40 years. Two weeks ago, Dr. John Halpern, an associate director of the
    substance-abuse research program at Harvard's McLean Hospital, presented
    his proposal for testing MDMA as a treatment for anxiety in terminal cancer
    patients to an institutional review board -- a body of scientists,
    ethicists and community members -- which approves and keeps tabs on studies.

    "It feels like we're getting close to opening the door to psychedelic
    research at Harvard, which has been shut since 1965, so these are exciting
    times," Doblin said.

    Halpern is also working with Bob Wold, a 51-year-old construction firm
    owner who suffered from debilitating cluster headaches, which are rare but
    brutal, until four years ago when he tried psilocybin to treat them. Wold
    had never used psychedelic drugs recreationally, and he was concerned and
    skeptical about using an illegal substance. But he was in the midst of
    choosing between three surgeries for his cluster headaches, each of which
    would have cost about $35,000. One involved a gamma knife to cut into his
    brain; the other two required holes drilled in his skull. Given those
    options, psilocybin didn't seem so radical.

    "(The psilocybin) broke my cycle" of headaches, Wold said. "There is
    nothing on the market now, and there never has been, that will actually
    break a cycle."

    Achieving relief from his nightmarish pain spurred Wold to start a
    movement. He now runs clusterbusters.com, where he communicates with about
    200 other cluster-headache victims who have tried psilocybin to relieve
    their pain. Wold has collected reams of data in the form of questionnaires,
    which Halpern can present to Harvard's institutional review board.

    Studies starting as early as the '30s that showed positive results treating
    cluster and migraine headaches with psilocybin and LSD helped Wold decide
    to try a psychedelic. The studies also showed success with other disorders
    including depression, alcoholism and addiction to other drugs like heroin.

    The Heffter institute's Greer saw firsthand the effects of MDMA on his
    patients in the early '80s. He synthesized his own MDMA (it was first
    synthesized by Merck in 1912) along with Alexander Shulgin, who became a
    cult figure for psychedelic enthusiasts. In 1986, Greer and his wife, Requa
    Tolbert, a clinical nurse, published the first and what is still the
    largest body of data on the therapeutic effects of ecstasy.

    Greer hoped eventually to discover the mechanism of MDMA, which stands for
    3,4-methylenedioxy-N-methylamphetamine, and get it approved as a
    prescription drug for certain ailments. But starting in 1985, the tone of
    psychedelic research changed. Ecstasy had become a popular street drug, and
    the DEA declared MDMA a schedule 1 drug, the highest level of illegal drug
    in the United States. Anyone caught using or distributing ecstasy,
    including doctors, would face fines and jail time, and Greer stopped
    prescribing it for his patients.

    "The government was funding a lot of research about abuse of psychedelic
    drugs," Greer said, "but no one was funding research to use them to
    understand how the brain works or to treat people with psychological or
    medical problems."

    Another reason progress has been slow is because NIDA-funded studies
    performed by Dr. George Ricaurte and Dr. Una McCann found that MDMA had ill
    effects on the brain. A 2002 study was particularly worrisome because it
    showed that ecstasy caused Parkinson's-like brain damage. But a year later,
    the researchers retracted the study because they discovered they had
    accidentally used methamphetamine instead of ecstasy.

    In the wake of these controversial results, psilocybin, the active
    ingredient in "magic mushrooms," seemed more acceptable to the FDA and DEA.
    Dr. Charles Grob, head of adolescent and child psychiatry at the
    Harbor-UCLA Medical Center, tried for almost a decade to get the go-ahead
    to perform a study using MDMA to treat anxiety in terminal cancer patients.
    He got permission in the early '90s to use the drug in a safety study on
    healthy volunteers, the results of which were published in Behavioral Brain
    Research in 1996, and the Journal of Magnetic Resonance Imaging in 1999.

    But what he really wanted was to work with a patient population. When after
    several years neither the FDA nor the DEA went for the idea, he changed his
    proposal.

    "By the late '90s felt it felt hopeless to work with MDMA because it had
    gotten such a negative reputation, so we revamped the study to work with
    psilocybin," Grob said. "In 2003, it was accepted."

    Due to the strict guidelines for the study, however, only two patients out
    of the 12 necessary to complete the trial have participated in the study,
    and another is lined up.

    Dr. Francisco Moreno at the University of Arizona has administered
    psilocybin to eight obsessive-compulsive disorder patients. His study,
    which began in 2001, was the first FDA-approved clinical trial involving a
    psychedelic in 30 years. He presented positive results at a recent
    scientific meeting, and is in the process of publishing his data in a
    medical journal.

    "I'm very optimistic for the future," Grob said. "I think these compounds
    have tremendous untapped potential to be utilized within medicine and
    psychology. I think they need to be demystified, andsafety parameters need
    to be established and studied. But with good controls, I think they can be
    used safely and effectively."

Comments

To make a comment simply sign up and become a member!